Literature DB >> 7160044

Pharmacokinetic study of indicine N-oxide in pediatric cancer patients.

M M Ames, J S Miser, W A Smithson, P F Coccia, C S Hughes, D M Davis.   

Abstract

Pharmacokinetics of the experimental antitumor agent indicine N-oxide were investigated in a group of 23 pediatric cancer patients. Plasma elimination of indicine N-oxide was best described by a two-compartment open model. The mean plasma distribution phase half-life, plasma elimination phase half-life, and plasma clearance were 8 min, 84 min, and 62 ml/min/m2 (2.1 ml/min/kg), respectively. One patient with renal impairment had an abnormally long plasma elimination phase half-life (275 min) and reduced plasma clearance (17 ml/min/m2). Plasma elimination phase half-life values increased and plasma clearance values decreased with increasing age of the pediatric patients. Plasma elimination of indicine N-oxide was more rapid in this group of children than in adults who had previously received the drug.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7160044     DOI: 10.1007/bf00257237

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

1.  Indicine-N-oxide: the antitumor principle of Heliotropium indicum.

Authors:  M Kugelman; W C Liu; M Axelrod; T J McBride; K V Rao
Journal:  Lloydia       Date:  1976 Mar-Jun

Review 2.  The toxic actions of pyrrolizidine (senecio) alkaloids.

Authors:  E K McLean
Journal:  Pharmacol Rev       Date:  1970-12       Impact factor: 25.468

3.  Degradation and clearance of methotrexate in children with osteosarcoma receiving high-dose infusion.

Authors:  Y M Wang; P Y Kim; E Lantin; D C van Eys; M M Romsdahl; W W Sutow
Journal:  Med Pediatr Oncol       Date:  1978

4.  Clinical pharmacology. Drugs in children.

Authors:  G Rylance
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-03

5.  Toxicity and pharmacokinetics of a pyrrolizidine alkaloid, indicine N-oxide, in humans.

Authors:  J S Kovach; M M Ames; G Powis; C G Moertel; R G Hahn; E T Creagan
Journal:  Cancer Res       Date:  1979-11       Impact factor: 12.701

6.  PLasma half-life and urinary excretion of cyclophosphamide in children.

Authors:  N E Sladek; J Priest; D Doeden; C J Mirocha; S Pathre; W Krivit
Journal:  Cancer Treat Rep       Date:  1980 Oct-Nov

7.  Determination of indicine N-oxide and indicine in plasma and urine by electron-capture gas-liquid chromatography.

Authors:  M M Ames; G Powis
Journal:  J Chromatogr       Date:  1978-12-11

Review 8.  Pediatric clinical pharmacology. A practical review.

Authors:  G Udkow
Journal:  Am J Dis Child       Date:  1978-10

9.  Phase II trial of indicine N-oxide (INDI) in patients with advanced colorectal carcinoma.

Authors:  W C Nichols; C G Moertel; J Rubin; A J Schutt; J C Britell
Journal:  Cancer Treat Rep       Date:  1981 Mar-Apr

10.  Activity of indicine N-oxide in refractory acute leukemia.

Authors:  L Letendre; W A Smithson; G S Gilchrist; E O Burgert; C H Hoagland; M M Ames; G Powis; J S Kovach
Journal:  Cancer       Date:  1981-02-01       Impact factor: 6.860

View more
  1 in total

Review 1.  Dehydropyrrolizidine Alkaloid Toxicity, Cytotoxicity, and Carcinogenicity.

Authors:  Bryan L Stegelmeier; Steven M Colegate; Ammon W Brown
Journal:  Toxins (Basel)       Date:  2016-11-29       Impact factor: 4.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.